Subject : A survey to understand the overall treatment landscape of partial onset seizure with focus on lacosamide
Epilepsy is characterized by recurrent seizures caused by abnormal neuronal discharges in the brain. Epilepsy is the third leading contributor to the global burden of disease for neurological disorders the global burden of disease for neurological disorders and affects 65 million people worldwide. According meta-analysis of international studies, the prevalence of epilepsy is 6.4 cases per 1,000 persons and the annual incidence is 67.8 cases per 100,000 person-years.
It is estimated that there are more than 10 million persons with epilepsy (PWE) in Indiavii.Its prevalence is about 1% in our population. The prevalence is higher in the rural (1.9%) compared to urban population (0.6%).viii, ix Prevalence of partial seizures, especially complex partial seizures, are a significant concern, ranging from 49% to 61.3% in various studies
Lacosamide is a functionalized amino acid that has antiseizure properties. It has simple pharmacokinetics, low potential for drug–drug interactions and is usually well tolerated with no known significant end-organ toxicities
Halász P et.al a multicenter, double-blind, placebo-controlled trial randomized patients study showed median percent reduction in seizure frequency per 28 days from baseline to maintenance period (intent-to-treat, ITT) was 20.5% for placebo, 35.3% for lacosamide 200 mg/day (p = 0.02), and 36.4% for 400 mg/day (p = 0.03). In the per protocol population, the reductions were 35.3% for lacosamide 200 mg/day (p = 0.04) and 44.9% for 400 mg/day (p = 0.01) compared to placebo (25.4%). The 50% responder rate for lacosamide 400 mg/day (40.5%) was significant (p = 0.01) over placebo (25.8%).x Another study showed median percent reductions in seizure frequency per 28 days from baseline to maintenance (intention-to-treat, ITT) were 37.3% for lacosamide 400 mg/day (p = 0.008) and 37.8% for lacosamide 600 mg/day (p = 0.006) compared to 20.8% for placebo, with responder rates of 38.3% and 41.2%, respectively, compared to placebo (18.3%, p < 0.001; ITT)
So various studies have demonstrated the efficacy and tolerability of adjunctive lacosamide and support that lacosamide may be an advantageous option for the treatment of partial-onset seizures in patients with epilepsy.
we are conducting this survey to survey to understand the overall treatment landscape of partial onset seizure with focus on lacosamide
As you will be spending some extra time to give your feedback on the questionnaire based on your clinical experience, we offer to pay you by cheque a professional fee of Rs {{$contractAmount}}, on receiving the completed Survey Questionnaire Form from you.
We trust you and we are partners in promoting safe and effective drug therapy. In that spirit we hope you will consent to participate in this survey. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}
}})